Lifeboat Foundation

If you look up ‘scientific overachiever’ in the dictionary, you’re likely to find a two-word definition: George Church.

The American geneticist, molecular engineer, and chemist splits his time between roles as Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT. He’s also a member of the National Academy of Sciences, acts as an advisor to a plethora of cutting edge companies, and heads up synthetic biology at the Wyss Institute for Biologically Inspired Engineering, of which he’s a founding member.

Oh, and George is author to hundreds of published papers, 60 patents and a popular science book (also, theoretically, George Church may live in an alternate reality where there are more than 24 hours in a day).

Tooth loss is a concern that most people will face at some point in their life. According to studies, by the age of 74, 26 percent of adults will have lost all of their permanent teeth. Dentures are sufficient, but they’re uncomfortable and dental implants can fail and have no ability to “remodel” as the surrounding jaw bone changes with age.

All of these are reasons why some people have placed their hope in stem cell research. While there are controversy surrounds the new medical method such as the use and destruction of human embryos, not all research involves human tissue and has the potential to change a lot of lives.

A new technique being tested in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, Edward V. Zegarelli prof of odontology, and a professor of biomedical engineering at Columbia University, could make “tooth loss” a thing of the past. The cluster believes they need to find some ways to own the body’s stem cells, migrate it to a three-dimensional scaffold manufactured from natural material and insert it to a patient’s mouth.

Interesting research paper on a new nanobot technology. I’m watching for ways in which suitable substrates for mind uploading can be constructed, and DNA self-guided assembly has potential.

Here are some excerpts and a weblink to the paper:

“…Chemical approaches have opened synthetic routes to build dynamic materials from scratch using chemical reactions, ultimately allowing flexibility in design…”

Continue reading “Dynamic DNA material with emergent locomotion behavior powered by artificial metabolism” »

The insulin pumps diabetics currently rely on do a great job of delivering the hormone as needed, but need regular replacing due to what are known as fibrils. These form over a day or two as insulin compounds accumulate into clumps and create the risk of blockages, but scientists in Australia have engineered what they say is a safer alternative, with egg yolks serving as their starting point.

The formation of fibrils means that diabetics need to replace their insulin pumps every 24 to 72 hours to avoid the risk of dangerous blockages, which bring with them a risk of life-threatening under-dosing. Beyond the dangers to the patient’s well-being, the need to regularly replace the pump increases the workload needed to manage their disease and means that portions of the medicine often go to waste.

So, there is considerable interest in developing synthetic insulin that doesn’t behave in this way. Researchers at Melbourne’s Florey Institute of Neuroscience and Mental Health approached this problem through a new technique it developed with scientists in Japan, whereby the insulin is engineered from egg yolks to allow for greater freedom over the final design.

A newly published study has described the successful results in mice of a novel vaccine designed to prevent neurodegeneration associated with Alzheimer’s disease. The researchers suggest this “dementia vaccine” is now ready for human trials, and if successful could become the “breakthrough of the next decade.”

The new study, led by the Institute for Molecular Medicine and University of California, Irvine, describes the effect of a vaccine designed to generate antibodies that both prevent, and remove, the aggregation of amyloid and tau proteins in the brain. The accumulation of these two proteins is thought to be the primary pathological cause of neurodegeneration associated with Alzheimer’s disease.

The research revealed the vaccine led to significant decreases in both tau and amyloid accumulation in the brains of bigenic mice engineered to exhibit aggregations of these toxic proteins. Many prior failed Alzheimer’s treatments over the past few years have focused individually on either amyloid or tau protein reductions, but growing evidence suggests a synergistic relationship between the two toxic proteins may be driving neurodegeneration. Hence the hypothesis a combination therapy may be the most effective way to prevent this kind of dementia.

A Mars invasion, a climate meeting and human–animal hybrids are set to shape the research agenda.

The second thing to mention is that in many instances, we actually have cracked it, at least medically. There are endless cutting-edge treatments being deployed as we speak, and endless additional cutting-edge research projects being conducted. There are new breakthroughs all the time, much of which are awaiting FDA approval, but one thing many of these treatments and cures have in common is that they are developed in a tiny country smaller than New Jersey that happens to be located in perhaps the worst neighborhood on Earth. When it comes to cancer research, Israel leads the way.

Finally, the last time I wrote about cutting-edge cancer treatments, I was contacted by a close friend who is a leading oncologist. He pointed out that a disclaimer is very much necessary when I write these articles. The last thing oncologists need is for their patients to think there is some magical solution here and show up to their appointments with a cut-out of an article. In fact, the last thing a cancer patient needs is false hope.

So the disclaimer is that this company is in the clinical trial phase, and if all goes according to plan, tumors might be much more manageable and treatable than they are today, but a lot has to happen before we get there.